About Wanbury
Incorporated in 1988, Wanbury is an integrated pharmaceutical company primarily focused on active pharmaceutical ingredients (APIs), alongside branded formulations. It operates two USFDA-approved manufacturing facilities at Tanuku, Andhra Pradesh and Patalganga, Maharashtra, with cumulative installed reactor capacity of 500 KL. Its formulations business is primarily domestic, while around 80% of API sales are exported to more than 50 countries. FY25 sales were INR 600 Cr., with APIs contributing 88% and formulations 12%.
Why We Recommend Wanbury
The report gives Wanbury a Positive outlook but does not state a formal Buy, Hold or Sell recommendation.
- Established API positions: Wanbury has estimated company market shares of ~11% in Metformin, ~30% in Sertraline and ~11% in Tramadol. Metformin and Sertraline made up 50% and 40% of FY25 API sales mix, respectively.
- Debt refinancing and turnaround: In Mar’25, the company refinanced debt from 21% NCDs to 12.5% for up to INR 175 Cr. Infomerics subsequently upgraded its rating to IVR BBB-/Stable from IVR C+/Negative/Issuer Not Cooperating.
- New API launches: After commercializing an anaesthetic in Q4FY26, the company plans four new additions each year from FY27. Planned molecules include Dextromethorphan HBr, Ketamine HCl, Rivaroxaban and Sitagliptin.
- Margin improvement: Process benchmarking with E&Y has supported raw-material cost optimization through improved input-output ratios and higher batch yields. Wanbury targets API gross margins of 50%+.
- Capacity and cash generation: Tanuku has potential for brownfield expansion, with the company targeting reactor capacity of 600KL from the existing 500KL. The report notes CFO remained positive from FY19 to FY25.
Wanbury Key Financials
| Particulars | FY24 | FY25 | H1-FY26 | 9M-FY26 |
|---|---|---|---|---|
| Op. Revenues | 578 | 600 | 323 | 486 |
| Growth Y-o-Y % | 15.6% | 3.8% | 10.6% | 13.6% |
| EBITDA | 72 | 76 | 50 | 77 |
| EBITDA % | 12.5% | 12.7% | 15.5% | 15.8% |
| PAT | 56.0 | 30.5 | 28.7 | 44.4 |
| PAT % | 9.7% | 5.1% | 8.9% | 9.1% |
| Total Debt | 116 | 177 | 196 | |
| Equity | 28 | 59 | 107 | |
| Debt / Equity | 4.14x | 2.98x | 1.83x |
Operating revenue rose to INR 600 Cr. in FY25 from INR 578 Cr. in FY24. In 9M-FY26, revenue was INR 486 Cr. and EBITDA margin was 15.8%.
Valuation and Target Price
Wanbury trades at a PE(x) of 15.7x annualized 9MFY26 PAT. The report describes the stock as a “Growth at Value” pick and says sales growth alongside sustainable margins could support potential upward re-rating. Q4FY26 results and management commentary are key monitorables. The report states a Positive outlook but provides no target price, upside or formal Buy, Hold or Sell rating.
- INR 266
- CMP
- INR 929 Cr.
- Market capitalization
- Positive
- Outlook
Key Risks
- Product concentration and commoditization: APIs contribute ~88% of total sales, while Metformin and Sertraline account for ~90% of API revenues. Metformin faces intense competition and limited pricing power; Sertraline has better entry barriers.
- Debt and repayment obligations: As on Sep’25, debt of INR 196 Cr. against equity of INR 107 Cr. translated into Debt to Equity of 1.83x and Debt to EBITDA of 1.95x. Quarterly repayments of Investec NCDs were scheduled to start from 20-Feb’26.
- Launch and capex execution: The plan to launch four products every year from FY27 is exposed to regulatory risks, approval timelines and the challenge of reaching commercial scale.
Business and Growth Plans
- API portfolio: The existing portfolio comprises six molecules. Metformin and Sertraline are the largest contributors to API sales; the report characterizes Metformin as a high-volume, low-price commodity-like API and notes regulatory complexity as a moat for Sertraline.
- Pipeline and revenue potential: The planned API launches are being developed in-house. The company expects them to contribute INR 60-70 Cr. in incremental revenues, translating into 7-9% of growth p.a.; it targets gross margins of 50%.
- Capital expenditure: Planned capex is INR 64 Cr. in FY26 and INR 63 Cr. in FY27, to be funded primarily through internal accruals and existing NCDs.
- Formulations: The branded formulations portfolio covers several therapeutic areas and supplements. The business uses fully outsourced manufacturing and emphasizes brand building; the network includes 300+ field force, 1,800+ distributors and 30,000+ doctors engaged.
Management
The report describes Wanbury as having an operating track record of over 37 years in the pharmaceutical industry, led by an experienced promoter group involved in the company’s strategic direction and turnaround.
Our View
The report’s positive view rests on the financial turnaround, recent margin expansion, established positions in select APIs and a planned launch pipeline. High product concentration, debt repayments and the execution required for launches and capex remain important risks. Q4FY26 results and management commentary are identified as key monitorables.